行情

CALA

CALA

Calithera生物科学
NASDAQ

实时行情|Nasdaq Last Sale

5.24
-0.04
-0.76%
盘前: 5.44 +0.2 +3.82% 08:00 07/02 EDT
开盘
5.26
昨收
5.28
最高
5.35
最低
5.07
成交量
55.42万
成交额
--
52周最高
8.18
52周最低
2.450
市值
3.69亿
市盈率(TTM)
-3.0203
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CALA价格均价为11.50,最高价位20.00,最低价为9.00。

EPS

CALA 新闻

更多
Edited Transcript of CALA earnings conference call or presentation 7-May-20 9:00pm GMT
Thomson Reuters StreetEvents · 06/04 20:22
Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 06/02 12:00
Calithera Biosciences To Present Telaglenastat KEAPSAKE Trial In Progress Poster At ASCO
Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today
Benzinga · 05/29 12:37
Calithera Biosciences to Present Telaglenastat KEAPSAKE Trial in Progress Poster at ASCO20 Virtual Annual Meeting
The KEAPSAKE study (NCT04265534) will explore telaglenastat versus placebo in combination with a standard-of-care regimen of immunotherapy and chemotherapy as first-line treatment for patients with non-small cell lung cancers (NSCLC) with KEAP1/NRF2 mutations.
GlobeNewswire · 05/29 12:00
Calithera to Present at the Jefferies Virtual Healthcare Conference
Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commi
GlobeNewswire · 05/27 11:01
Has Calithera Biosciences (CALA) Outpaced Other Medical Stocks This Year?
Zacks · 05/18 16:30
Is Calithera Biosciences (CALA) Stock a Solid Choice Right Now?
Zacks · 05/13 14:15
What Makes Calithera (CALA) a New Buy Stock
Zacks · 05/11 17:00

所属板块

生物技术和医学研究
-0.33%
制药与医学研究
+0.20%

热门股票

代码
价格
涨跌幅

CALA 简况

Calithera Biosciences, Inc.是一家临床阶段的制药公司。该公司专注于发现和开发对抗在肿瘤微环境中控制关键代谢通路的肿瘤和免疫细胞靶标的小分子药物。它开发满足肿瘤细胞和抗癌免疫细胞(例如细胞毒性T细胞)代谢需求的药剂。该公司主要候选产品CB-839是肿瘤细胞中的关键酶。该公司正在开发用于血液和肿瘤指征的其他候选产品CB-1158。CB-1158是精氨酸酶的有效性和选择性口服生物抑制剂。CB-839是人类谷氨酰胺酶的选择可逆性口服生物抑制剂。CB-1158在已证实通过免疫机制作用的同基因小鼠肿瘤模型中具有单一试剂抗肿瘤活性。该公司于期临床试验中针对实体瘤患者测试CB-1158。
展开

微牛提供Calithera Biosciences Inc(NASDAQ-CALA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CALA股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CALA股票基本功能。